Sometimes the difference between ordinary and unforgettable is as simple as making the dip from scratch. Across kitchens ...

Wegovy has been approved for use among the growing number of Americans who have MASH. By Dani Blum The Food and Drug Administration approved the weight loss drug Wegovy to treat an increasingly ...

Please provide your email address to receive an email when new articles are posted on . We were unable to process your request. Please try again later. If you continue to have this issue please ...

Wegovy can now be used in adults with metabolic-associated steatohepatitis (MASH) who have excessive scar tissue in their liver. The FDA has expanded Wegovy use to include adults with ...

Semaglutide (Wegovy) is the first GLP-1 receptor agonist approved for MASH with liver fibrosis, excluding cirrhosis cases. The phase 3 ESSENCE trial demonstrated significant liver outcome improvements ...

Targeting GLP-1 receptors now has the FDA’s blessing as a way to treat the fatty liver disease called MASH with Novo Nordisk’s weekly injectable drug Wegovy becoming the second approved treatment for ...

With a new endorsement from the FDA, Novo Nordisk’s Wegovy has picked up its third indication and become the second drug approved in a severe form of fatty liver disease. Shortly after market close ...

Wegovy's new indication for noncirrhotic MASH with liver fibrosis is the first GLP-1 receptor agonist approved for this condition. The Phase III ESSENCE trial showed significant improvements in ...

Michter’s has evolved from a defunct Pennsylvania brand into one of Kentucky’s most respected whiskey producers, known for its limited-edition releases. The US*1 Toasted Barrel Finish Sour Mash builds ...

The US Food and Drug Administration (FDA) has granted accelerated approval for Wegovy® (semaglutide) as a treatment for adults with moderate to advanced metabolic dysfunction-associated ...

Bagsværd, Denmark, 15 August 2025 – Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved an additional indication for Wegovy ® (semaglutide 2.4 mg) based on a ...

Danish big pharma Novo Nordisk has been given the go-ahead for its star weight loss drug, Wegovy (semaglutide), in patients with metabolic dysfunction-associated steatohepatitis (MASH) who have ...